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Abstract 
Nanoparticles as drug delivery vehicles have been well tested and transferred into clinical 
practice in the past few decades. The success of most nanocarriers is attributed to their 
biocompatibility, controlled release and unique size-dependent properties. In this regard, I 
proposed that starch nanoparticles (SNPs) might be a good candidate for drug delivery due to 
their excellent biocompatibility. The crosslinked SNPs supplied by EcoSynthetix Inc. are 
nanogel-like materials with many potential advantages, including good biocompatibility, 
biodegradability, and high capacity for loading drugs. In addition, SNPs can be engineered to 
achieve targeted delivery and sustained release of drugs. So far the SNPs from EcoSynthetix are 
only used commercially in the paper coating industry. The chemical modifications of SNPs are 
expected to generate new materials that can be used for drug and gene delivery. Since the safety 
of nanomaterial is of great concern in biomedical applications, one objective of this research is to 
study the toxicity of the unmodified and modified SNPs. Through my research, the reason for the 
toxicity is attributed to free crosslinker molecules present in the sample, and they can be 
removed by washing. For drug loading study, doxorubicin (Dox), a highly effective clinical 
anticancer drug, was chosen as the model drug. Due to the significant side effects of Dox, it is 
important to develop targeted delivery vehicles to decrease its toxicity to the healthy tissues. 
While several biocompatible nanocarriers have been developed to deliver Dox, the synthesis of 
these vehicles is often complicated and expensive. Compared to these delivery platforms, the 
SNPs are renewable and can be produced commercially on a large scale. Therefore, the second 
objective is to synthesize and characterize carboxyl-modified SNPs for Dox loading. The drug 
loading/release kinetics and the efficacy of drug complex were studied and compared to that of 
the free drug. Finally, cationic SNPs developed by a co-worker were evaluated and utilized for 
DNA delivery. DNA adsorption onto the cationic SNPs was investigated, and then the cellular 
uptake efficiency of the DNA/SNPs complexes was were tested and formed to be comparable to 
a commercial gene transfection agent. This new generation of SNP platform holds great promise 
for the treatment of cancer in the future. 
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Chapter 1 Introduction 
1.1 Cancer and cancer therapy 
Cancer refers to out-of-control cell growth that can invade normal tissues. Many people 
around the world are suffering from more than 100 types of cancers.1 Based on the report from 
the American Cancer Society, cancer is the second largest cause of death in the US and 589,430 
Americans are expected to die due to cancer in 2015.2 Current cancer treatments include surgery, 
radiation therapy, chemotherapy and other methods. Each treatment has pros and cons depending 
on the cancer types, location and patient status. Surgery and radiotherapy are highly targeted 
treatments to remove the entire malignant tumor. However, once the cancer has spread 
throughout the body via metastases, these methods have limited impact. Moreover, surgery and 
radiotherapy require good patient conditions due to their high invasiveness.3 
Chemotherapy is another treatment commonly used to control the growth of tumors by 
drug administration. These drugs can suppress tumor cell replication via targeting cell mitosis.3 
However, chemotherapeutic drugs kill not only cancerous cells, but also healthy cells. The 
effectiveness of chemotherapy is limited by their toxic side effects, including hair loss, weight 
loss, vomit, skin sensitization, and immunosuppression. Another major limitation to effective 
chemotherapy is drug resistance.4 The amount of drug reaching target cells is insufficient to kill 
cancer cells, therefore dosage must be increased. However, a high dosage also enhances the risk 
of toxic side effects to normal tissues.4 Therefore, it is urgent to develop targeted chemotherapy 
to cancer cells and decrease side effects to normal tissues. 
1.2 Advantages of nanomaterials as drug carriers 
As the emerging nanotechnology is moving at a fast pace, the application of 
nanotechnology in biomedicine has attracted intense research interest in recent years.5 
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Nanotechnology involves nanomaterials with at least one dimension having a size between 1 to 
100 nanometers. Compared to free drugs, nanoscale vehicles can offer many advantages, such as 
enhanced drug solubility, protection from unspecific interaction, longer circulation time, 
improved targeting efficiency, and controlled release at specific sites.5 The cell uptake of 
nanocarriers is greatly affected by the physicochemical properties of nanoparticles, drugs, and 
environmental parameters.5 A systemic understanding of such effects is vital for the successful 
design and development of drug delivery vehicles. In this section, some key properties of 
nanomaterials affecting drug delivery are discussed. 
1.2.1 Size of nanomaterials 
It is generally accepted that nanoparticles with a diameter of 10-100 nm are suitable for 
cell uptake.6 Smaller particles (< 5 nm) are easily cleared by glomerular filtration in the kidneys, 
while particles larger than 100 nm have low permeation into tumor cells. Researches show that 
40-50 nm of nanoparticles have the highest uptake efficieny.7 It is considered that the 
internalization mechanisms of particles with various sizes may be different. When particles are 
larger than 1 μm, they are internalized mainly through the phagocytosis mechanism. Smaller 
nanoscaled particles enter cells through the pinocytosis mechanism via unspecific and/or specific 
interaction with cell membrane followed by internalization.7 Therefore, the size range of 
nanomaterials allows it to possess a longer biological half-life compared to small molecular 
cancer drugs. 
1.2.2 Surface properties of nanoparticles 
The loading capacity of various drugs can be achieved through covalent bonding, 
hydrophobic interaction, electrostatic interaction, etc.5 Many hydrophobic drugs have low 
solubility. To achieve high-performance therapy, a high concentration of drugs is always 
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required. Therefore, it is beneficial to improve the solubility of drugs using nanocarriers. Ideally 
nanocarriers can prevent unspecific interactions with the biological environment, and protect 
drugs from unnecessary degradation. Additionally, multiple types of drugs with different 
functionalities can be co-delivered using the high surface area of nanomaterials. Drug release 
inside the cell can be controlled by environmental stimuli if responsive functional groups are 
attached to the surface of nanomaterials. 
Surface charge is another important factor affecting the internalization of nanoparticles. 
Positively charged particles may interact electrostatically with the cell membranes containing  
negatively charged phospholipid head groups, which facilitates the cellular binding and uptake. 
The internalization pathway could be controlled by endocytic modes due to the creation of holes 
in the membrane. Macropinocytosis could be an important mechanism for positively charged 
particles.8 Particles with negative charges may interact with cell membrane proteins. The 
internalization was suggested to be a dymamin-independent manner. More studies are required to 
investigate the exact pathway for the internalization of the nanoparticles with various charges. 
Non-specific interactions of nanoparticles (either negative or positive) with proteins or other 
components in serum may induce elevated clearance.  
1.2.3 Passive and active targeting 
Nanocarriers offer a unique high efficiency of drug delivery into the tumor cells via either 
passive or active pathways. The passive pathway can be explained by the enhanced permeation 
retention (EPR) effect shown in Figure 1. Typically, tumor cells have leaky blood vessels. To 
maintain rapid cell growth, tumor tissues show high vascular permeability, allowing more 
nutrients and oxygen into the tumor cell. Macromolecules with molecular weight (MW) larger 
than 40 kDa prefer to accumulate in the tumor tissues. As a result, retained nanocarriers with a 
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similar size can concentrate and then release drugs into the tumor cells. Although passive 
targeting is a popular strategy, limitations still exist. For example, certain tumors or some part of 
tumors do not exhibit the EPR effect. One promising strategy to overcome the limitations is to 
use active targeting.  
 
Figure 1. Targeted delivery of nanocarriers into the tumor cells via two mechanisms: passive 
targeting (EPR effect) and active targeting (receptor targeting). This figure is adapted from ref. 5 
Copyright 2007, Nature Publishing Group. 
 
Active targeting involves the functionalization of nanocarriers with targeting chemical 
ligands. These nanocarriers with targeting ligands can recognise specific groups called receptors 
on the cell surface. After targeting cancer cells with receptors at the surface (shown in Figure 1), 
the nanocarriers will be internalized into the tumor cells, followed by the drug release. The 
specific binding to cell surface receptors facilitates the accumulation of drugs into cancer cells. 
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Compared to free drugs and passive targeting, active targeting can increase the possibility of 
tumor cell uptake, improve therapeutic effects and decrease side effect to normal cells. Selecting 
the suitable targeting receptors plays a vital role in the successful design of an active targeting 
nanocarrier. Receptors overexpressed on the cancer cell surface are preferred, such as human 
epidermal growth factor receptor 2 (HER2) in breast cancers, the folate receptor in ovarian 
cancer, luteinizing-hormone-releasing hormone (LHRH) receptor in many cancers. Targeting 
ligands can be screened based on the receptor of tumor cells. Aptamers, proteins, antibodies and 
their fragments are the most widely used ligands.9 Peptides also have been used as targeting 
ligands due to their easy preparation, low cost, and enhanced resistance to enzymatic 
degradation.9 
1.2.4 Biocompatibility and biodegradability 
Many types of nanomaterials have been developed as drug delivery vehicles over the past 
few decades. Although each type of drug-carriers has its unique advantages and drawbacks, their 
safety as carriers in drug delivery systems causes great concern. Some inorganic nanomaterials 
possess optical and magnetic properties, but it is hard to ignore their inflammatory effect and 
toxicity on cells after repeated administration.10 For examples, studies have shown that 
nanoparticles of titanium oxide can induce DNA damage and cell death.11 Carbon nanotubes, as 
emerging drug delivery platforms, have been reported to cause granulomas in lungs of laboratory 
animals.12–14 As a result, research has focused on developing more biocompatible nanoparticles, 
such as liposomes and biocompatible polymeric nanoparticles. To avoid the unspecific 
interactions with plasma proteins, the surface of nanoparticles is typically modified with non-
charged hydrophilic PEG chains via PEGylation. Several studies have shown that PEGylated 
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nanoparticles have longer circulation time in vivo.15,16 Optimization of PEG molecular weight 
and layer thickness is required to achieve the best efficacy.  
1.3 Nanomaterials as drug delivery vehicles 
Over the past few decades, many types of nanomaterials have been developed as drug 
delivery vehicles. Besides their unique size and surface properties, each nanomaterial offers 
additional functionalities to improve the pharmacokinetics and pharmacodynamics of cancer 
drugs. Herein, three widely investigated nanocarriers (liposomes, polymeric nanomaterials, and 
inorganic nanoparticles) are introduced. The properties, applications and development of these 
nanocarrier platforms are introduced in the following sections.  
1.3.1 Liposome-based drug delivery 
Liposomes, spherical vesicles of lipid bilayers, have attracted strong interest for 
biomedical applications. The physicochemical properties of liposomes are determined by the 
hydrophilic headgroups, linkers and hydrophobic tails. For example, the thickness of the bilayer 
and the phase transition temperature (Tm) of liposomes depend on the length of the carbon chain. 
The charge and type of headgroups control the interaction modes of liposomes with proxy 
molecules. Incorporation of synthetic lipids into naturally occurring liposomes provides rich 
possibilities for biomedical applications.17 
Liposomes as drug delivery vehicles represent the first generation of nanoparticle drug 
delivery platforms and are still the most successful systems. Due to their amphiphilic structures, 
liposomes can carry both hydrophobic and hydrophilic drugs. Several liposome-based 
therapeutics (e.g. Doxil, AmBisome, and DepoCyt) have been approved by FDA.17 In 1995, 
Doxil (doxorubicinHCl liposome injection, Janssen Biotech, Inc) was approved to treat AIDS 
related Kaposi’s syndrome.18 Compared to the free drug Dox, Doxil offers a ~100-times longer 
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half-life and a reduction in cardiotoxicity. However, Doxil also shows some unwanted adverse 
effect, such as skin toxicity, which has not been observed for free Dox. These early approved 
liposomal drugs typically only contain original liposomes and delivered drugs (Figure 2A). 
While the simple system achieves great success, the drawbacks are obvious. For example, 
liposomes may eliminate entrapped drugs before the EPR effect could induce cell targeting due 
to their instability. To improve the targeting efficiency, ligands with recognition capability are 
attached to the surface of liposomes (Figure 2B). These active targeting ligands include proteins, 
aptamers, peptides antibodies and their fragments. Incorporating antibodies or antibody 
fragments into liposomes are the most common strategy for active targeting due to their high 
affinity toward receptors. Even with improved targeting efficiency, the unwanted leakage of 
drugs may still occur due to the unspecific interaction of liposomes with plasma proteins. One 
popular strategy is to modify the liposome surface with PEG chains (Figure 2C). The “stealth” 
PEG coatings also increase the circulation time. PEGylated liposome vincristine shows a 66-fold 
decrease in clearance compared to the free drug vincristine.15 Furthermore, if a cleavable linker 
(e.g., S-S bond) is used, detachable PEG coating can be realized.19 A simple combination of 
targeting ligands and surface blocking can result in novel nanocarriers with combined 
performance (Figure 2D). Now versatile conjugation strategies provide liposome more 
functionality for enhanced targeting (Figure 2E). For example, combination of liposome with 
magnetic nanoparticles provides magnetic resonance molecular imaging in cancer therapy.  
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Figure 2. Development of liposome platforms as drug carriers in different stages. (A) 
Unmodified liposome can deliver both (a) hydrophilic drugs and (b) hydrophobic drugs. (B) 
Antibody as targeting compound can be (c) covalently attached or (d) incorporated into the 
membrane. (C) (f) A protective layer is formed by (e) PEG modification. (D) PEG layer and 
antibody (g, h) are combined to modify the liposome. (E) More surface functionalization 
strategies, including (i) protective polymer layer, (j) antibody attached polymer layer, (k) 
diagnostic labelling, incorporation of (l) positive charged lipids for (m) DNA adsorption, (n) 
responsive liposome or (o) polymer, (p) cell-penetrating peptide, (q) viral component, and (r) 
functional magnetic particles or (s) noble metal nanoparticles. This figure is adapted from ref. 20 
Copyright 2005, Nature Publishing Group. 
 
Although liposome-based drug delivery platforms exhibit promising results in both lab 
and clinic, challenges still exist, especially for active targeting. For example, the diffusion and 
internalization may be inhibited by the presence of targeting molecules. Also, unspecific 
interactions with serum proteins may deactivate the active targeting. Therefore, subsequent 
works are required to examine various environmental factors in the clinical applications.  
1.3.2 Polymer-based drug delivery  
Polymers are another widely studied drug delivery platform for cancer therapy. Both 
natural polymers (dextran, hyaluronic acid, chitosan) and synthetic polymers (PEG, 
poly(vinylpyrrolidone) (PVP)) have shown great possibilities as drug delivery systems.21 
Additionally, diverse structures of polymers (e.g. linear polymers, branched polymers, graft 
polymers, dendrimers) provide advantages for rational carrier design. The terminology “polymer 
therapeutics” was coined to describe five types of polymer-based drugs, including polymeric 
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drug, conjugates of polymers with proteins, complexes formed between DNA and polymers, 
conjugates of polymers with small molecular drugs, and block copolymer micelles loaded with 
drugs (Figure 3).21  
 
Figure 3. Scheme of representative polymer-based drug delivery platforms. This figure is 
adapted from ref. 21 Copyright 2003, Nature Publishing Group. 
1.3.2.1 Polymeric drugs 
Certain natural polymers possess intrinsic antitumor activity. For example, divinyl ether 
and maleic anhydride copolymer (DIVEMA) have been shown to exhibit antitumor, antibacterial, 
and antifungal activities.21 However, DIVEMA failed in clinical trials due to its high toxicity. 
Researchers turn their attention toward modifying natural polymeric drugs to decrease toxicity. 
Sulfated dextrin22 shows anti-HIV type 1 activity by blocking T-cell lines infection. Besides 
natural polymers, synthetic counterparts also attracted a lot of attention. Glatiramer acetate 
(COPAXONE, Teva Pharmaceuticals) is a synthetic polypeptide composed of four amino acids: 
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L-ananine, L-lysine, L-glutamic acid and L-tyrosine. With a myelin basic protein mimic property, 
COPAXONE is approved by FDA for reducing the frequency of relapses.23 While polymeric 
drugs have intrinsic biological activities, most polymers used in drug delivery systems should be 
non-toxic.  
1.3.2.2 Polymer-drug conjugates  
Cancer drugs can be small molecules, proteins, antibodies and DNA dependent on the 
action mechanism. In a biological environment, these drugs suffer from poor stability and 
inefficient cell targeting. For example, to improve the stability of protein-based drugs, PEG was 
conjugated to protein drugs in the 1970s.24 The incorporation of a PEG chain also provides 
proteins with several advantages: increased solubility, reduced immunogenicity, and prolonged 
plasma half-life. Due to these excellent advantages, several PEG-protein drugs have been 
approved and have reached the market.25 Additionally, combining polymer with small molecule 
drugs can improve the targeting efficiency. Typically, a responsive linker group is used to link 
the polymer chain with the drug. As a result, unnecessary degradation can be avoided during the 
transport process. After accumulating on the targeting cell, the linker group is cleaved and the 
drug is released. Some popular strategies include enzyme-cleavable linkers and pH-sensitive 
linkages.  
1.3.2.3 Polymeric micelles 
Block copolymers can form micellar structures via self-assembly. Hydrophobic cancer 
drugs can be simply encapsulated into the core of the micelle. One polymeric micelle-based 
nanocarrier, Genexo-PM, has been approved in Korea in 2007 and has entered phase II clinical 
stage in the USA.26,27 The entrapping method is simple for formulation. However, the 
disadvantages are obvious. The drug loading efficiencies may be affected by many 
11 
 
environmental factors such as solvent, temperature, hydrophobicity of polymer chain, and 
property of drugs. Additionally, combination of drug conjugation and entrapping into the core of 
micelle can achieve multi-drugs delivery. Kolishetti and co-workers reported the conjugation of 
Pt(IV) pro-drug into the poly(lactic acid) (PLA) chain, and entrapped doxetaxel into the core of 
polymeric micelles formed with PLGA-PEG-COOH using the nano-precipitation method (Figure 
4).16 Their work demonstrated that the co-delivery of drugs with different physicochemical 
properties could be achieved by self-assembled polymeric micelles.16 
 
Figure 4.  Co-delivery of Pt(IV) pro-drug and docetaxel by self-assembled polymeric micelles. 
This figure is adapted from ref. 16 Copyright 2010, The National Academy of Sciences. 
1.3.3 Inorganic nanomaterials  
Liposome- and polymer-based nanomaterials represent the most successful nanocarriers 
for cancer drugs until now. However, many potent drugs have limited abilities to be loaded into 
liposomes or polymer nanocarriers and need more suitable platforms. Inorganic nanoparticles 
have unique size dependent optical, electric, and magnetic properties. Therefore, using inorganic 
nanoparticles for drug delivery can provide additional functionalities, such as magnetic 
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resonance imaging and remote controlled release. Also, the surface of inorganic nanoparticles 
can be easily functionalized via many conjugating strategies to provide multiple functionalities.  
1.3.3.1 Gold Nanoparticles (AuNPs) 
One of the major issues faced by chemotherapy is the low solubility of hydrophobic 
drugs. Paclitaxel, a mitotic inhibitor, has shown great impact in cancer treatments; however, its 
anticancer efficacy is limited due to its low aqueous solubility. Although many lipid- and 
polymer-based nanocarriers successfully improved the solubility, these encapsulation methods 
gave a relatively large particle size. Zhang and co-workers28 prepared a drug-nanoparticle hybrid 
by covalently linking Paclitaxel onto the surface of DNA modified gold nanoparticles. As shown 
in Figure 4, the DNA linker was labeled with two functional linking groups, a thiol and amine 
group, and a fluorescent dye. The DNA was conjugated with drugs (modified Paclitaxel) through 
EDC/Sulfo-NHS coupling chemistry; meanwhile, DNA was conjugated with AuNPs through the 
well-established thiol-gold chemistry. Three common problems related to Paclitaxel could be 
solved with this platform: 1) the solubility of Paclitaxel was enhanced in both buffers and cell 
culture environments. 2) The drug efficacy was increased. 3) Combined with the potent optical 
property of AuNPs, the movement of nanocarriers can be monitored. Besides DNA, other linkers, 
such as hexaethylene glycol, have also been reported to covalently attach Paclitaxel to AuNPs.29  
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Figure 4. Schematic representation of conjugation Paclitaxel with AuNPs via a DNA linker. This 
figure is adapted from ref. 28 Copyright 2011, American Chemical Society. 
 
1.3.3.2 Magnetic Nanoparticles (MNPs) 
MNPs are promising drug carriers due to their unique magnetic field responsiveness. 
Upon application of an external magnetic field, MNPs can accumulate at specific sites until the 
release of contained drugs. Additionally, hyperthermia can be achieved under an external 
alternative magnetic field (AMF). Initially, micro-sized magnetic particles were used to deliver 
various drugs. For example, Widder and co-workers30 used magnetic albumin microspheres to 
deliver Dox with 100-fold higher dose than for the free drug. However, the microsize of 
magnetic particles limits their surface area and drug loading capacity. Lübbe and co-workers31,32 
pioneered the work using nanosized magnetic particles as drug delivery vectors later on.  
To obtain a high drug loading capacity, the MNPs are typically modified with an organic 
or inorganic shell. The core structure of the composites maintains the magnetics properties, and 
the shell captures and releases drugs. For example, Gang and co-workers33 synthesized a poly(ε-
caprolactone) (PCL) modified Fe3O4 NPs to load anticancer drug gemcitabine in the polymer 
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shell. A significant antitumor activity was observed at a dose 15-fold lower than for the free 
drugs. It is considered that attaching PEG on the particle surface could further enhance the 
delivery efficacy. The PEG molecules can minimize the reticuloendothelial system (RES) uptake 
and systemic clearance of nanoparticles. Yu and co-workers reported a cross-linked 
(trimethoxysilyl)propyl methacrylate-γ-PEG methacrylate-coated superparamagnetic iron oxide 
nanoparticles and used this conjugate to deliver Dox (Figure 5).34 The drug Dox with positive 
charge was adsorbed by the carboxylic groups on the particles surface via electrostatic attraction. 
A significant antitumor activity at low dose (8-fold lower than the free drug) was achieved even 
without an external magnetic field due to the EPR effect. The magnetic core of the composite 
used in this work offers the capability of magnetic resonance imaging instead of therapeutic 
benefits.  
 
Figure 5. Scheme of formation of supermagnetic iron oxide nanoparticles for Dox loading. This 
figure is adapted from ref. 34 Copyright 2008, Wiley-VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
 
While AuNPs, magnetic NPs and other inorganic NPs have been developed as drug 
delivery carriers, limitations of these platforms still exist. For example, the strength of the 
external field applied to magnetic NPs at specific sites may be limited, due to the gradual 
15 
 
decrease of the magnetic field. Another issue is the unknown toxicity of the inorganic 
nanoparticles and their degradation products to humans.  
1.4 Nanomaterials as gene delivery vehicles 
Gene therapy is using functional nucleic acids as drugs to treat genetic disorders.35 To 
achieve gene regulation therapy, a key issue is the development of useful gene delivery vehicles 
because free DNA or RNA is rapidly degraded in the blood. Until now two categories of vehicles 
have been involved in gene delivery: viral and nonviral vectors. The early works focused on viral 
vectors,35 such as adenoviral vectors and retroviral vectors. While efficient gene transfer was 
obtained using viral vectors, high concern on the safety have limited their development.36 
Nonviral vector systems have attracted a large amount of research interest in the past decade. 
The advantages of nonviral vectors include excellent biocompatibility and their easy scale up for 
manufacturing. Most of current works are focusing on engineering nanomaterials with high gene 
transfer efficiency and stability in vivo. Typical nonviral vectors are cationic liposomes and 
cationic polymers.37  
As early as 1979, the delivery of DNA into cells using cationic lipids was demonstrated.38 
Typically, cationic liposome, for example, 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) 
and N-[1-(2,3-dioleyloxy)propyl-]-N,N,N-trimethylammonium chloride (DOTMA), are used to 
bind to negatively charged DNA mainly through electrostatic interaction. Researchers have 
found that the cationic head groups, the hydrocarbon tails, and the linking groups affect the gene 
delivery efficiency.36 Since DNA can be condensed through electrostatic interaction, a 
straightforward strategy to improve transfection efficiency is to increase the charge density of the 
polar head groups. For example, the liposomes formed with dioctadecylamidoglycylspermin 
(DOGS), a lipid with multiple headgroups, exhibit elevated DNA delivery capability.39 Also, 
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replacing the ammonium groups with phosphonium or arsonium40 can significantly decrease the 
cytotoxicity and increase transfection efficiency. While head groups are directly related to DNA 
binding, the hydrophobic tails also affect the delivery performance. Studies indicate that the 
liposomes with lipids having a shorter carbon chain show higher transfer efficiency (e.g. C14 > 
C16 >C18).41 The cytotoxicity of liposome vectors is considered to be from the cationic 
headgroups.37  
Cationic polymers also have been used as gene delivery vectors for a long time. 
Polyethylenimine (PEI), well known as the gold standard for gene delivery, is the most famous 
cationic polymer for gene delivery. Since Behr’s initial work in 1995,42 PEI and its various 
derivations have been proved to be effective gene transfer vectors. Jones and co-workers37 have 
summarized that five important parameters need to be considered when designing a polymeric 
gene delivery system, including the charge density, binding site, functional group, molecular 
weight, and stability.37 Nitrogen containing groups of cationic polymers are typically used as the 
DNA binding sites. The DNA binding capability of cationic groups on polymers follows the 
order: quaternary > tertiary > secondary > primary43; but it is interesting to note that tertiary 
amines rather than quaternary amines is claimed to achieve the highest gene delivery 
efficiency.44 The cytotoxicity of polymer-based vectors is dependent on the chemical structure of 
the polymer backbone. Chemical bonds that readily hydrolyze in physiological conditions are 
preferred to esters, phosphoesters, and amides. 
Besides these two classical gene delivery vectors, novel vectors based on quantum dots,45 
metal nanoparticles,46 and carbon nanotubes47 have been reported to possess high transfer 
efficiency as well. However, the major drawback of these inorganic nano-vectors is their 
unknown cytotoxicity. 
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1.5 Starch and starch nanoparticles 
Although many drug and gene delivery vehicles have been developed in the laboratory, 
only limited platforms have the potential to be commercialized. Safety issues still exclude most 
new nano-vehicles. The success of most nanoparticle drug delivery platforms is attributed to 
their biocompatibility. In this regard, the use of natural products with excellent biocompatibility 
is still the best choice, even though some physicochemical properties may be sacrificed. 
Therefore, biocompatible materials such as starch are considered as being good candidates for 
drug delivery vehicles. However, two aspects limit the development of starch as drug vehicles. 1) 
the size of native starch grain is too large (micrometer scale) and is not well-defined. 2) The drug 
loading capacity might be low due to the limited surface area and functional groups of 
unmodified starch. To transform starch into useful drug delivery vehicle, preparation of 
nanoscaled starch particles and surface modification become prerequisites.  
1.5.1 Structure and property of starch   
Starch is an environment-friendly, biodegradable and biocompatible polymer produced 
by many plants, such as potato, corn, rice, and wheat.48 As the major dietary source of 
carbohydrates, starch is the second most abundant biomaterial in nature. Besides food, starch can 
be used industrially to replace traditional materials due to its renewable and cost-effective 
advantages. To date, starch has already been investigated and used as a coating agent, thickener, 
adhesives, biodegradable filler in cosmetics and pharmaceuticals.49 
The main constituent of starch is glucose. Starch consists of two polysaccharides: 
amylose and amylopectin. Amylose is a linear polymer, in which glucose units are linked 
together via α-1,4 glycosidic bonds. Amylopectin is a larger branched polymer, in which glucose 
units are linked together via both α-1,4 and α-1,6 glycosidic bonds.48,50 Figure 6 illustrates the 
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structures of amylose and amylopectin. The size of amylopectin is much larger than that of 
amylose. Amylose has a molecular weight in the range of 105 to 106 g/mol, while amylopectin 
has a molecular weight in the range of 106-107 g/mol. Starch consists of 15-20 wt% amylose and 
80-85 wt% amylopectin.50 Starch particles are stored in plants in the form of granules. The size 
of a starch granule depends on the species of the plant and ranges from 1 to 200 μm.51  
 
Figure 6. Molecular structures of glucose-based polysaccharides. A) Amylose with α-1,4 
glycoside bonds. B) Amylopectin with both α-1,4 and α-1,6 glycoside bonds.50 
 
Due to its polymeric structure and large particle size, native starch is hardly soluble in 
cold water. Although starch can be dispersed in water by gelatinization at high temperature, it 
becomes insoluble again upon reducing temperature.49 Starch has high viscosity once it gels. The 
poor solubility and high viscosity of starch make it difficult to modify and this limits its potential 
industrial applications. However, modifications can improve the physical properties of starch and 
add more functional groups to starch. After modification, starch can replace more traditional 
materials in various fields. As a result, different techniques have been studied to reduce the size 
and improve the solubility of starch.  
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1.5.2 Starch Nanoparticles (SNPs) 
1.5.2.1 Preparation of SNPs  
In most recent studies, the conventional preparation process of SNPs is performed by 
chemically crosslinking starch molecules with appropriate crosslinking agents. Starch molecules 
are obtained by degradation of granular starch. Enzymes, acids and bases are commonly utilized 
to open the structure of natural starch.52 Many crosslinking agents have been investigated to 
improve the properties of natural starch for different applications, including glyoxal,53 
phosphorus oxychloride54, sodium tripolyphosphate,55–58 sodium trimetaphosphate,52 
diepoxybutanes,59 epichlorohydrin,60–62 citric acid,63,64 dicarboxylic acids,65 anhydrides,66 and 
dialdehydes67. Those agents typically have at least two binding sites, which can crosslink starch 
together by forming ester or ether bonds. The available crosslinking sites of starch are their 
abundant hydroxyl groups. Figure 7 illustrates two possible crosslinking processes of starch in 
basic conditions. One is crosslinked with epichlorohydrin by creating ether linkages,61 and the 
other one is crosslinked with sodium trimetaphosphate by creating ester linkages.52 The physical 
strength of starch is enhanced by introducing crosslinkers.54,68 The size of SNPs can be 
controlled in the nanometer range through different crosslinking densities.  
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Figure 7. Two crosslinking process of starch using A) epichlorohydrin61 and B) sodium 
trimetaphosphate52 as crosslinking agents. Copyright 1999, Plenum Publishing Corporation. 
 
These crosslinking reactions can be carried out in batch or continuously by reactive 
extrusion. As a traditional method, a batch process is performed in a vessel under continuous 
stirring. Since the native starch has poor solubility and high viscosity once it gels, relatively low 
starch concentration (35-45 wt%), high salt concentration (10-30 wt%) and low temperature (< 
A 
B 
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60 ◦C) are typically used in the batch process to overcome starch gelatinization.69 Extra steps 
associated with additional cost are also needed to remove salt at the end of the process. 
Additional issues with the batch process are poor reaction selectivity and longer reaction time.69 
On the other hand, the extrusion process can overcome these problems. The extruder has a great 
mixing ability and is usually applied to deal with the high viscosity processes, such as those 
resulting from gelatinized starch.70 Compared to the batch process, higher starch concentration 
(60-80 wt%) and higher reaction temperature (70-140 ◦C) can be handled in an homogeneous 
reaction medium.69 As a result, the reaction rate is improved up to 15 folds over the batch 
process.71 Twin screw extruders are generally preferred over single screw extruder, because of 
the extra screw designed to add reagent and remove by-products, which provides excellent 
control of mixing and short residence time (2-5 minutes).69,70 
1.5.2.2 EcoSphereTM nanoparticles: preparation and structure 
The SNPs used in my project were supplied by EcoSynthetix Inc. They were prepared by 
reactive extrusion on a large scale. They are produced by feeding a crosslinker and plasticizer to 
starch in a twin screw extruder and reacting the mixture at elevated temperature.72,73 Solid starch 
nanoparticles finally exit the extruder as an agglomerate after water evaporates. The 
agglomerates of solid SNPs are shown in Figure 8.  
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Figure 8. EcoSphereTM starch nanoparticles agglomerate produced from extruder. Image is 
adapted from ref. 72 
 
The melting point of native starch is higher than its decomposition temperature.74,75 As a 
result, plasticizer needs to be added to avoid starch decomposition.73 The function of the 
crosslinking agent is to bind the starch chains together; therefore, they must have at least two 
sites to react with starch. In this case, glyoxal was used as crosslinking agent. Glyoxal can link 
starch nanoparticles together by reacting with the hydroxyl groups to form hemiacetals and 
acetals. Figure 9 illustrates the hypothesized crosslinking process of starch with glyoxal under 
acidic conditions. The possible structures of crosslinked SNPs are shown in Figure 10. It is 
worthy of note that the crosslinking process is reversible in aqueous solution. NMR techniques 
have been applied to characterize the crosslinkers in SNPs. Most glyoxal is involved in 
crosslinking but these crosslinkers can be partially released when crosslinked SNPs are dispersed 
in water.76  
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Figure 9. Crosslinking process of starch using glyoxal as crosslinking agent. R-OH is the 
hydroxyl groups on starch backbones.76 
 
Figure 10. The possible structure of crosslinked SNPs.76 
 
As a new nanomaterial, the structure and properties of SNPs need to be characterized. A 
hypothesized SNP structure is illustrated in Figure 11.77 It has been proposed that the SNPs are 
bound together by intramolecular and intermolecular crosslinkers. The strucute of  
intermolecular crosslinker in SNPs is also shown in Figure 11. These intramolecular and 
intermolecular crosslinkers are believed to stabilize SNPs and decrease the swelling ratio of 
SNPs compared to native SNPs. The size of SNPs was reported by Gross’s group78 using 
dynamic light scattering (DLS).78 Measurements were performed in DMSO and water. Their 
DLS results show that the size distribution of SNPs have two peaks around 45 and 300 nm in 
both solvent.78 The smaller particles are attributed to the isolated starch nanoparticles; while the 
larger paticles are from the aggregated particles. The Gross’s group also performed SEM to 
analyse the structure of SNPs (Figure 12), which is in good aggrement with DLS results.79,78  
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Figure 11. Hypothesized structure of crosslinked SNPs. 77 
 
Figure 12. SEM of native starch granules and ESEM of EcoSphereTM starch nanoparticles. This 
figure is adapted from ref. 79 Copyright 2005, Elsevier Ltd. 
1.5.3 Starch and starch nanoparticles for drug and gene delivery  
1.5.3.1 Common modifications to starch and starch nanoparticles  
With a poor solubility and high viscosity, starch has limited application in industry. 
Chemical modifications can improve certain properties of starch and add more functional groups 
to starch. Meanwhile, the abundant hydroxyl groups on glucose units making up the chain 
provide sites to be modified with multifunctional groups.80,81 Consequently, various chemical 
modifications of starch have been studied. Three kinds of common modifications are anionic, 
cationic and hydrophobic modifications.  
Anionic starch can be obtained by oxidizing hydroxyl groups of starch into carboxyl 
groups. The oxidation process is generally achieved by hypochlorite oxidation82,83 and ozonation 
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oxidation.84 Hypochlorite salt, as a traditional oxidation agent, is easy to handle in an industrial 
environment. However, hypochlorite oxidation has the obvious drawback of producing large 
amounts of salts that need to be disposed of.85 On the other hand, ozone is a clean and powerful 
oxidation agent, which leaves no residues behind. But exposure to ozone can cause lung disease, 
which limits its application in industry and laboratory.86 Another modification is via the addition 
of anionic groups to starch, such as carboxymethyl starch.87–89 The present of carboxymethyl 
functional groups improves the solubility and reduces the gelatinization temperature of starch.89 
Carboxymethyl starch is widely used as a thickening, stabilizing, and water retaining agent to 
improve the quality of food.88 
Cationic starch is commonly produced by introducing cationic groups onto the backbone. 
The cationic reagents containing amino, ammonium, sulfonium or phosphonium groups can be 
introduced via an etherification reaction with the hydroxyl groups of starch.90–92 Conventionally, 
cationic starch is produced by etherification reaction of starch with quaternary ammonium 
groups.92–94 Ammonium groups can be introduced by cationic reagents, such as glycidyl 
trimethyl ammonium chloride and 3-chloro-2-hydroxypropyltrialkylammonium chloride.93,94 
Their chemical structures are shown in Figure 13. Cationic starch is widely used as flocculants in 
wastewater treatment and additives in the paper industry.43,91,46 Recently, it has been reported 
that cationic starch nanoparticles can be used as gene delivery vehicles.94 
 
Figure 13. Chemical structure of glycidyl trimethyl ammonium chloride and 3-chloro-2-
hydroxypropyltrialkylammonium chloride. 
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Chemical grafting is one of the most effective methods to produce hydrophobically 
modified starch with varied degrees of substitution.58,95 Numerous papers have reported the 
esterification of starch with long chain fatty acids to produce hydrophobic starch material.22,48-51 
Of the various hydrophobic modifications, starch acylation has proved to be the most 
commercially effective and a relatively easy method.99,100 Acylated starch is thermally stable and 
has lower gelatinization temperature compared to native starch.99–101 The excellent properties of 
the acetylated starch have potential applications as surface coating,100–102 and biomedical 
materials,58,81,98 and in the packaging industry.99,102 
1.5.3.2 Applications in drug and gene delivery 
In the early stage, even though starch has the obvious advantages of being a 
biocompatible, biodegradable, and cost-effective material, only a few studies have reported on 
the applications of starch for drug delivery. The reasons come from the limitations of the 
structure and physical properties of native starch. The native polymeric chain structure of starch, 
which has a particle size range of 1 to 200 μm, requires modification techniques to reduce the 
size to the nanoscale. Unfortunately, early attempts by scientists only reduced the particle size to 
the micro-scale, which limited the efficacy of starch as drug delivery vehicles.103,104 
As the emerging nanotechnology is moving at a fast pace, various nanoparticles have 
been tested as drug delivery vehicles and transferred to clinical practice in the past few decades. 
Due to the biocompatible advantages of starch, recent applications of SNPs derivatives as drug 
delivery platforms have attracted the interest of scientists. To become drug delivery vehicles, 
SNPs can be modified with various functional groups and added target ligands on their surface. 
Typically, the drug loading mechanisms include electrostatic attractions, hydrophobic 
interactions, coordination bonding and covalent conjugates.80 Zhao and coworkers105 reported 
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that the surface of SNPs can be conjugated with the active-targeting ligand folate modified with 
PEG. After the anticancer drug doxorubicin was loaded to modified SNPs, the targeting ability 
and inhibition effect to cancer cells were enhanced.105 Additionally, hydrophobic polymer 
grafted SNPs106 and di-aldehyde modified SNPs67 are also reported to have efficient loading and 
sustained releasing abilities for Dox. Fatty acids grafted SNPs also have been found to be good 
drug delivery vehicles for hydrophobic drugs, which is reported to strengthen the efficacy of 
model anticancer drug indomethacin.58 Furthermore, iron oxide impregnated SNPs are potential 
drug vehicles for magnetically targeted drug delivery.62 Figure 14 A) describes the binding 
process of cisplatin to magnetic SNPs via coordination conjugation. Figure 14 B) describes the 
possible drug complexes release profiles in targeting infected cells obtained by applying an 
external magnetic field. These modified SNPs provide a possible pathway to target cancer cells, 
deliver drugs with higher efficacy, and minimize side effects.  
 
Figure 14. A) Binding process of cisplatin to magnetic SNPs and B) The possible drug 
complexes release profiles in targeting cells by applying an external magnetic field. This figure is 
adapted from ref. 62 Copyright 2012, Elsevier Ltd. 
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For gene delivery, since unmodified SNPs do not interact with DNA strongly, the 
straightforward method to increase DNA affinity is via cationic modification of starch. One type 
of reported cationic modification is to graft the cationic biocompatible polymer polyethylenimine 
(PEI) to the surface of oxidized SNPs. The starch-graft-PEI synthesized by Lehr et al. achieved 
lower toxicity and better transfection efficacy of plasmid DNA than free DNA.107 Cationic 
groups can be added directly onto starch backbone. Recently, Kost and coworkers94 developed 
SNPs modified with a quaternary ammonium group for siRNA delivery. Their results show that 
the SNPs/siRNA complexes resulted in effective cellular uptake.  
1.6 Thesis objectives  
The goal of this research is to modify SNPs for drug and gene delivery. SNPs are a new 
material produced by EcoSynthetix Inc. in an industrial scale. So far SNPs are only being 
commercially used for paper coating. Since the safety of nanomaterial is a great concern for 
biomedical applications, one of this thesis objectives is to study the toxicity of unmodified and 
modified SNPs.  In particular, my thesis focuses on the toxicity of SNPs and the methods that 
can be applied to eliminate this toxicity. Meanwhile, the safe concentration range of SNPs used 
for drug and gene delivery was also tested and analyzed. In order to balance the safety and 
efficacy of a drug delivery system, the amount of modified SNPs employed as vehicles needs to 
be carefully controlled. Doxorubicin, an effective anticancer drug, is used as the model drug to 
be loaded onto modified SNPs. Therefore, the second objective of this thesis is to synthesize and 
characterize carboxyl-modified SNPs for doxorubicin loading. Finally, the cationic SNPs 
developed by Duncan Li in Dr. Taylor laboratory were characterized and utilized for DNA 
delivery. 
In summary, the specific objectives of this thesis for drug delivery are: 
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1. Study the origin of the toxicity of EcoSphereTM starch nanoparticles 
2. Synthesize and characterize oxidized SNPs with different oxidation levels 
3. Evaluate the effect of oxidation and washing on the toxicity of SNPs 
4. Investigate Dox loading properties 
5. Study Dox release from carboxylated SNPs 
6. Test the toxicity of drug conjugate and compare to free drug 
The specific objectives of this thesis for gene delivery are: 
1. Characterize cationic SNPs with different degrees of substitution 
2. Evaluate the effect of degree of substitution on the toxicity of cationic SNPs and compare the 
toxicity to other commercial gene transfection agents 
3. Investigate DNA binding to cationic SNPs 
4. Deliver DNA to cancer cells 
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Chapter 2 Toxicity of SNPs from EcoSynthetix and oxidized SNPs 
2.1 Introduction 
As SNPs are produced commercially by EcoSynthetix Inc. for paper coating, it is 
essential to investigate the safety aspect of the SNPs as drug delivery vehicles. In this chapter, 
the cytotoxicity of the unmodified SNPs supplied by EcoSynthetix Inc. was investigated. The 
reasons for the toxicity of the SNPs and the development of a methods to eliminate the toxicity 
were addressed. Additionally, the dose range of the modified SNPs used for drug delivery need 
to be carefully controlled in order to balance the safety and efficacy of the drug delivery system. 
In this study, a HeLa cell line was chosen to test the toxicity of SNP samples. HeLa is the 
first immortal cell line harvested from a cancer patient. Their robustness allows them to grow in 
a wide range of conditions.108 HeLa cell lines are widespread in the scientific community due to 
their robustness and fast replication every 24 hours.109 To test the safety of the SNPs as drug 
delivery vehicles, SNPs need to be incubated with cancer cells for an appropriate time to 
quantify cell viability. 
Cell viability can be measured via various assays. These automated methods are required 
to be sensitive, quantitative and reliable. The MTT assay is a standard colorimetric assay to 
quantify cell viability in high throughout, which is based on the conversion of yellow tetrazolium 
salt MTT into purple insoluble formazan by living cells.90 Live cells have reductase enzymes in 
mitochondria and these enzymes can reduce the yellow tetrazolium salt called 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into insoluble MTT formazan 
with a purple colour (Figure 15). This colour conversion occurs only when reductase enzymes in 
mitochondria are active. Therefore, the resultant colour is proportional to the number of the live 
cells.112,113 The absorbance at a specific wavelength can be quantified using a microplate reader. 
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The MTT assay has advantages of being less time consuming and cheap and having a relatively 
high throughout.91 The viable cells in 96-well plates can be measured via the fluorescence plate 
reader without the need for elaborate cell counting.91 In this research, all cell viability and 
toxicity are therefore measured via the MTT assay.  
 
Figure 15. The conversion of yellow tetrazolium salt MTT into insoluble formazan via reductase 
enzymes. 113  
2.2 Effect of crosslinker concentration on the toxicity of SNPs from EcoSynthetix 
SNPs with different crosslinking densities were obtained from EcoSynthetix Inc. These 
SNPs were prepared using reactive extrusion and are available in an industrial scale. Firstly, the 
toxicity of the SNPs with different crosslinking densities was tested. SNPs with 0%, 1%, 3%, 5% 
(w/w) crosslinker densities are abbreviated as GX0 GX1, GX3, GX5, respectively. “GX” 
represents the crosslinking agent glyoxal used by EcoSynthetix. Figure 16 shows the toxicity of 
the unmodified SNPs with different crosslinking densities. It shows that the SNPs with more 
crosslinkers have higher toxicity. In other words, the crosslinker might be the source of the 
toxicity of SNPs. In the manufacturing of SNPs, the amount of glyoxal as crosslinker added to 
GX0 to GX5 increases with the increasing crosslinking density. My co-worker Duncan Li used 
NMR techniques to characterize the crosslinkers in the unmodified SNPs. He found that free 
glyoxal molecules can be detected by NMR when the SNPs are dispersed in water and the 
amount of free glyoxal molecules calculated from the NMR spectra is less than that used in the 
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manufacturing of SNPs.76 According to these results, these free glyoxal molecules might have 
two sources: 1) a fraction of the glyoxal molecules are not involved in the crosslinking process of 
SNPs; 2) a fraction of the glyoxal molecules are released from the crosslinked SNPs when 
dispersed in water due to the reversible crosslinking reaction.  
 
Figure 16. The effect of crosslinking density on the toxicity of unmodified SNPs.  
 
To confirm the source of toxicity, we compared the toxicity of the GX0 sample spiked 
with an amount of glyoxal equal that used to prepare GX5 from EcoSynthetix. Figure 17 shows 
that the spiked GX0 sample has a trend similar to the actual GX5 sample from the company. As 
mentioned above, the amount of free glyoxal molecules detected from the NMR spectra is less 
than that used in the manufacturing of SNPs; while the amount glyoxal used to spike GX0 is the 
same as what is supposedly used in the manufacturing of GX5. As a result, the GX5 sample has 
slightly lower toxicity than the spiked GX0. These toxicity experiments confirmed that the free 
glyoxal molecules are at the origin of the toxicity of the unmodified SNPs.  
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Figure 17 Toxicity of spiked GX0 (GX0+glyoxal) and actual GX5 from the company. 
 
The mechanism of gyoxal toxicity was investigated for the first time by O’Brien et al. by 
studying the cytotoxic effect of gyloxal in isolated rat hepatocytes.114 The mechanism of gyoxal 
toxicity proposed by O’Brien et al. is shown in Figure 18.114 Briefly, glyoxal can induce lipid 
peroxidation (LPO) causing the formation of reactive oxygen species (ROS). Since glutathione 
(GSH) plays a protective role against ROS, excess ROS can lead to a decrease of GSH levels in 
cells. GSH also works as a catalyst in the production of glycolate. Consequently, decreased GSH 
level can decrease glycation leading to the collapse of the mitochondrial membrane. Finally, 
decreased GSH leads to more ROS formed which leads to more LPO. The formaldehyde formed 
in the LPO process could open the mitochondrial permeability transition pore (MPTP) to release 
cytochrome c and activate caspases, which lead to cell death.114 O’Brien et al. also reported that 
the cytotoxicity of glyoxal in rat hepatocytes depended on dose and time.114 The glyoxal toxicity 
was also studied in lung epithelial cell lines L132 NAD115 and E1A-NR3.116 The cytotoxicity of 
glyoxal is relatively lower in rat hepatocytes cell lines114 compared to that in lung epithelial cell 
lines L132 NAD115 and E1A-NR3.116 
100 1000 10000
0
20
40
60
80
100
120
C
el
l V
ia
bi
lit
y 
(%
)
Starch (g/mL)
 GX0
 GX5
 GX0+glyoxal
34 
 
 
Figure 18. The mechanism of glyoxal toxicity proposed by O’Brien et al.114 Copyright 2004, 
Elsevier Inc. 
 
Although the concentrations range of glyoxal (8 mM) used in the toxicity study of GX5, 
which represents the highest amount of glyoxal used to prepare the SNPs, is slightly higher that 
in isolated rat hepatocytes (5 mM) and lung epithelial cell lines (0.8 mM), the cytotoxicity effect 
of glyoxal in the HeLa cell lines is in good agreement with that in other cell lines.115,116 Knowing 
the cytotoxicity effect of glyoxal in cancer cells will help researchers to choose more suitable 
and safe crosslinking agents in the future manufacturing of SNPs. 
 
2.3 Effect of oxidation and washing on the toxicity of SNPs 
Doxorubicin (Dox) is used as the model drug in my research. For Dox delivery, drug 
delivery vehicles with a slight negative charge are typically perferred due to the positive charge 
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of Dox. Since SNPs are neural particles covered by hydroxyl groups, the hydroxyls can be 
oxidized into carboxyls with negative charges to achieve successful drug loading. Since SNPs 
can be precipitated out in ethanol, the washing process was performed in ethanol followed by 
centrifugation. As a result, the impurity and free glyoxal molecules can be separated into the 
supernatant and removed from the SNPs by ethanol washing. After oxidation and further 
washing, the oxidized SNPs with different crosslinking densities are almost non-toxic as shown 
in Figure 19.  
 
Figure 19. The effect of oxidation and washing on the toxicity of A) GX0, B) GX1, C) GX3, and 
D) GX5. 
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2.4 Summary and future work 
In this chapter, the toxicity of the unmodified and modified SNPs in the HeLa cell line 
was investigated by the MTT assay. The free glyoxal molecules were found to be the reason for 
the toxicity of unmodified SNPs. However, toxicity can be eliminated by the washing process. 
Finally, the washed and oxidized SNPs are almost non-toxic, which can be considered safe to 
deliver cancer drugs.  
Future studies can focus on the source of free glyoxal molecules. If some of the glyoxal 
molecules are not involved in the crosslinking process in the manufacturing of SNPs, the amount 
of glyoxal molecules actually involved in the crosslinking process should be determined. If the 
crosslinking process is reversible and glyoxal can be partially released from crosslinked SNPs 
when dispersed in water, the factors affecting the reversible crosslinking reaction and the 
methods to avoid or slow the reversible crosslinking reaction should be investigated. Since the 
toxicity of glyoxal has already been studied and reported by scientists, EcoSynthetix could 
employ more stable and safer crosslinking agents for the future development of SNPs for 
pharmaceutical applications. 
2.5 Materials and methods  
2.5.1 Materials  
SNPs with different crosslinker densities were provided by EcoSynthetix Inc. (Burlington, 
ON, Canada). The crosslinker densities were 0%, 1%, 3%, and 5% (w/w) of SNPs, and these 
SNPs were abbreviated as GX0 GX1, GX3, GX5, respectively. “GX” means that the crosslink 
agent used by EcoSynthetix Inc. was glyoxal. DMF, SDS, MTT, 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO), NaBr, and 5% NaClO (bleach) were purchased from Sigma–Aldrich 
(St Louis, MO). HEPES, NaOH, NaCl and DMSO were from Mandel Scientific (Guelph, ON, 
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Canada). Aqueous solutions were prepared using Milli-Q water (18.2 MΩ resistivity). HeLa cell 
line (CCL-2TM) was obtained from the American Type Culture Collection (ATCC, Manassas, 
Virginia) through the help of the laboratory of Dr. Shirley Tang (Waterloo, Ontario, Canada).  
2.5.2 SNP oxidation and washing 
The TEMPO-mediated oxidation of SNPs followed the protocol in the literature reported 
by Kato et al.82 The primary hydroxyl groups in the glucose unit of SNPs can be selectively 
oxidized into a carboxyl groups. 5% (w/w) SNPs was dispersed in 50 mL of Milli-Q water, then 
mixed with 23.75 mg TEMPO and 317.5 mg NaBr under stirring. Then SNPs was oxidized by 
the gradual addition of 5% NaClO (bleach) in an ice-water bath. TEMPO worked as a catalyst in 
the oxidation process. After each addition of the oxidant NaClO (5% bleach), the pH increased 
slightly before being followed by a steady decrease. For the reaction to proceed, the pH must be 
maintained around 10.75 by adding additional 0.5 M NaOH. The level of oxidation was 
determined based on the amount of NaOH used to produce carboxyl groups. For 20% oxidation, 
a total of 5 mL NaOH and 6.6 mL of NaClO was added gradually. Then the reaction was 
quenched by the addition of 3-fold ethanol to the mixture. Once oxidized SNPs were precipitated 
out in ethanol, the precipitate was centrifuged to remove the supernatant. Then the yellowish 
pellet was re-dispersed in water and re-precipitated in ethanol. This process was carried out three 
times. 
2.5.3 Cytotoxicity study of SNPs  
Cell culture. In this research, a HeLa cell line was used as the cancer cell model to study 
the toxicity of SNPs. The HeLa cell line was cultured in DMEM/F12 medium containing 10% 
v/v fetal bovine serum (FBS), 10% v/v of 100 U/mL penicillin-streptomycin, and kept in a 
humidified 5% CO2 incubator at 37 °C.  
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MTT assay. The toxicity of SNPs with different crosslinker densities was evaluated 
using the MTT assay. Firstly, 100 μL of HeLa cells suspension in DMEM/F12 cell medium was 
seeded at densities of around 5,000 cells per well in 96-well plate (costar), followed by the 
incubation for 24 h in 5% CO2 and 95% humidified cell incubator at 37 °C. After 24h incubation, 
the stock solution of SNPs (5% w/w in water), oxidized SNPs, and washed SNPs with different 
crosslinker densities (0%, 1%, 3%, and 5% w/w) were diluted to the desired concentrations. The 
culture medium was removed and replaced with 100 μL of freshly prepared culture medium 
containing various SNP samples. The cells were further incubated with samples for 72 h in the 
cell incubator. Next, 5 mg/mL of MTT stock solution was prepared in PBS. The culture medium 
was removed and replaced with 100 μL of freshly prepared culture medium. 25 μL of MTT stock 
solution was added to each well of the treated cells except blank wells. 25 μL of PBS was added 
to the wells with untreated cells as control groups. After the plates were incubated for 2 h in the 
cell incubator, 100 μL of extraction buffer (20% SDS in 50% DMF, pH 4.7) was added to each 
well and then incubated for 4 h in the cell incubator. The absorbance of the resultant purple 
colour was measured at 570 nm using a microplate reader (SpectraMax M3). All the wells were 
prepared in triplicate. Cell viabilities were averaged and normalized to the untreated cells, which 
worked as negative controls cultured in the cell medium without sample added. 
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Chapter 3 TEMPO oxidized SNPs for drug loading 
3.1 Introduction 
In this chapter, the capability of oxidized SNPs for drug loading was evaluated. 
Doxorubicin (Dox) was used as the model drug. As an effective clinical anticancer drug, Dox 
also has significant side effects. It is necessary to develop targeted delivery vehicles to decrease 
the toxic effects to the healthy tissues. Many materials have been tested for this purpose and the 
approved platforms so for include liposomes and biodegradable polymers. However, the 
synthesis processes of these vehicles are complicated and not cost-effective. Compared to these 
delivery platforms, our SNPs are renewable and can be produced on an industrial scale. Due to 
the positive charge of doxorubicin hydrochloride (DoxHCl), negatively charged vehicles are 
supposed to enhance the drug loading capacity. Therefore, SNPs need to be modified with 
anionically functional groups to achieve drug loading. Since the main constituents of SNPs are 
glucose units, the chains of SNPs contain many hydroxyl groups. By TEMPO-mediated 
oxidation, the primary hydroxyl moieties of the SNPs can be oxidized into carboxyl groups. 
After oxidation, Dox can be loaded onto carboxyl SNPs by electrostatic interactions. The drug 
adsorption and release profiles can be investigated. Finally, the efficacy of the drug complexes 
was tested and compared with free Dox.  
3.2 TEMPO oxidation of SNPs  
To introduce carboxylic acids, TEMPO-mediated oxidation was used to selectively 
oxidize SNPs. The key advantage of TEMPO oxidation is its selective oxidation toward primary 
hydroxyls (C6 position in Figure 20). The selective oxidation of polysaccharides by TEMPO-
mediated was firstly reported by Nooy et al.117 A subsequent study of selective oxidation on 
starch was performed by Kato et al.82 They examined the oxidation process in detail and 
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proposed a two-step oxidation mechanism. They suggested that hydroxyl groups are first 
oxidized into aldehydes, and then NaOH activates the carbonyls to form intermediates for the 
second oxidation into carboxylic acids as shown in Figure 20. 
 
Figure 20. Brief and detailed scheme of TEMPO-mediated oxidation of SNPs.82 R-OH stands for 
the primary hydroxyl groups on SNPs. 
 
The structure and catalytic action of TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl) is 
shown in Figure 20. Each glucose unit has a primary hydroxyl at the C-6 position, while other 
TEMPO 
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hydroxyls are secondary. Using TEMPO as a catalyst, only the primary hydroxyls at the C-6 
position can be oxidized into carboxylic acids.83 The oxidation also requires NaBr as a co-
catalyst and NaClO as an oxidation agent. A controlled amount of NaClO was added to allow for 
the oxidation of SNPs. The oxidation proceeded with a corresponding pH drop. Meanwhile, the 
pH needed to be maintained around 10.75 by adding NaOH for the reaction to proceed. As 
shown in Figure 20, each mole of NaOH consumed is supposed to produce a molar equivalent of 
intermediate structures, which are then completely oxidized into C6 carboxyls. As a result, the 
level of oxidation is controlled by the amount of NaOH consumed to reach the final neutral pH. 
Different oxidation levels of SNPs (1, 2, 5, 10, and 20%) were synthesized to investigate the 
effect of oxidation level on drug loading capacity. 
3.3 Spectroscopic characterization of oxidized SNPs 
3.3.1 UV-vis absorption spectroscopy of SNPs 
To confirm the oxidation extents of SNPs, the UV-vis absorption spectra of different 
oxidation levels of SNPs (1, 2, 5, 10, and 20%) were measured. Figure 21 shows the UV-vis 
spectra of SNPs at different oxidation levels and the change of SNP peak intensity at 253 nm as a 
function of oxidation level. As shown in Figure 21A, the non-oxidized SNPs does not show any 
peak from 220 nm to 600 nm. With just 1% oxidation, an intense peak at 253 nm can be 
observed, which is assigned to the absorbance of the newly generated aldehydes which are 
oxidation intermediates. TEMPO-mediated oxidation of SNPs proceeds via a two-step 
mechanism at the primary hydroxyl group; the first oxidation converts the hydroxyl into an 
aldehyde, while the second oxidation converts the aldehyde into a carboxylic acid as shown in 
Figure 20. This peak intensity doubles with 2% oxidation. Beyond 2% oxidation, the peak 
growth slows down, with barely any change being observed from 5 to 20% oxidation. After that, 
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the peak starts to decrease with further increase in oxidation. With 100% oxidation, the peak has 
completely disappeared. Figure 21B shows the absorbance of the oxidized SNPs at 253 nm 
which was assigned to the aldehyde groups that are intermediates during the oxidation reaction. 
When the oxidation level was increased from 1% to 5%, a large amount of aldehyde groups was 
produced. However, when the oxidation level is increased from 5% to 20%, the rate of aldehyde 
generation is similar to that of their conversion into carboxylic acids, resulting in a flat aldehyde 
concentration in this oxidation range. Once the oxidation level is higher than 20%, the second 
TEMPO oxidation step dominates. The aldehydes are converting into carboxylic acids more 
quickly than they are  generated. The concentration of aldehyde groups starts to decrease with 
further oxidation. At 100% oxidation, all aldehydes are converted into carboxylic acids. 
 
Figure 21. A)UV-vis spectra of SNP at different oxidation levels. B) the change of SNP peak 
intensity at 253 nm as a function of the oxidation level. 
3.3.2 Physical properties of oxidized SNPs  
To understand the property of the oxidized products, my co-worker Howard Tsai 
measured the variations in nanoparticle size and surface charge after TEMPO oxidation. 
Dynamic light scattering (DLS) was used to measure the size distribution of the SNPs. Results 
A B 
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showed that the hydrodynamic diameter (Dh) of the unmodified SNPs is 20 to 30 nm, which is in 
good agreement with previous findings.118 The 1%, 2%, and 5% oxidized SNPs have a particle 
size around 10 nm. Compared with the non-oxidized SNPs, the decreased size suggested the 
some level of degradation during the oxidation process. SNPs with oxidation levels equal to 10% 
and 20% have a broad size distribution from 10 nm to 130 nm. To explain the broad size 
distribution, we proposed that the small fragments of degraded SNPs aggregate via hydrogen 
bonding networks of different sizes. Higher levels of oxidized SNPs have more carboxyl groups 
to hydrogen-bond with SNPs hydroxyls, resulting in a broader size distribution. 
The ξ-potential measurements were used to measure the surface charge of SNPs after 
oxidation. Unmodified SNPs showed a potential close to zero due to its non-charged hydroxyl 
groups on the surface. With increasing oxidation level, the ξ-potentials of oxidized SNPs 
gradually decreased at basic conditions, reflecting a gradual increase in negative charge on the 
surface of the oxidized SNPs. As expectated, carboxylate anions are present on the SNP surface 
under basic conditions. Higher oxidation levels of SNPs with more carboxylate anions can result 
in higher negative surface charge. 
3.4 Oxidized SNPs for doxorubicin loading  
3.4.1 Doxorubicin and its delivery  
Doxorubicin (Dox) is one of the most effective anti-cancer drugs. The structure of 
doxorubicin hydrochloride (DoxHCl) is shown in Figure 22. Dox can directly intercalate DNA 
and stop the process of replication, eventually leading to apoptosis.119 In addition, the orange 
fluorescence of Dox makes it easy to quantify and track. However, the side effects of Dox are of 
great concern. Dox not only kills cancer cells, but also can accumulate in healthy tissues such as 
heart, liver, spleen, and bone marrow.119 The major drawbacks of Dox are the poor bio-
44 
 
distribution and low selectivity for targeting cancer cells. Due to the widespread distribution of 
Dox in the whole body, the amount of Dox reaching the targeted cells is not sufficient to kill 
cancer cells. As a result, dosage has to be increased. However, the high doses of drugs also 
enhance the risk to normal tissues.120 In addition, the solubility of Dox needs to be enhanced to 
reduce its precipitation in the aqueous circulation system.119 Therefore, it is important to develop 
drug delivery vehicles for Dox to target cancer cells and decrease the damage of healthy tissues.  
 
Figure 22. Structure of doxorubicin hydrochloride (DoxHCl). 
 
Various drug delivery platforms have been reported for Dox delivery in the last few 
decades. Doxil® is a doxorubicin loaded poly(ethylene glycol) coated (PEGylated) liposome, 
which was approved by FDA in 1995 and reached the market for the treatment of ovarian and 
breast cancer.121,122 PEG, as a biocompatible polymer, coats the surface of liposome to ensure its 
stability and protect drugs from the immune response. Studies have shown that a PEGylated 
liposome has a prolonged circulation in the blood and can release Dox in a controlled manner.122 
Other biocompatible nanomaterials, such as polysaccharides, have also been involved as 
nanocarriers for Dox delivery. Effective controlled and sustained release profiles of Dox from 
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PEG-modified dextran NPs123 and pH-responsive dextran-g-cholesterol micelle124 have been 
reported. Active targeting delivery of Dox is also achieved using targeting ligands conjugated to 
SNPs105 and dextran NPs125 via receptor-mediated pathways. Among these platforms, vitamin 
folic acid (folate) has been widely used as target ligand because of its selectivity to breast and 
ovarian cancer cells.105,125–127  
3.4.2 Adsorption of Dox 
After Dox has been adsorbed onto the oxidized SNPs by electrostatic interactions, an 
obvious fluorescence quenching of Dox was observed. Therefore, Dox adsorption onto SNPs can 
be monitored using fluorescence quenching. To systematically study the adsorption mechanism, 
the fluorescence of Dox was monitored when Dox was titrated with the oxidized and non-
oxidized SNPs. Figure 23A and 23B illustrate the intensity and shape changes of the 
fluorescence emission spectra during the Dox titration process by the oxidized and non-oxidized 
SNPs. Figure 23C plots the fluorescence peak intensity change of Dox at 550 nm as a function of 
the concentration of the SNPs. Figure 23D plots the fluorescence quenching efficiency of Dox as 
a function of the concentration of the SNPs. As shown in Figure 23C, for the oxidized SNPs, the 
fluorescence intensity of Dox gradually decreases with increasing concentration of the oxidized 
SNPs. In the case of Dox titrated with non-oxidized SNPs, no obvious fluorescence quenching is 
observed unless the concentration of SNPs was very high. As shown in Figure 23D, the 
quenching efficiency of oxidized SNPs is higher than that of non-oxidized SNPs at the same 
concentration. Since the functional groups on the non-oxidized SNPs are unlikely to interact with 
Dox, Dox may be just physically trapped by the SNPs. This trapping is attributed to the gel-like 
structure of the unmodified SNPs. 
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Figure 23. Dox titration process with oxidized SNP or non-oxidized SNP: Fluorescence emission 
spectra of Dox in different amounts of A) oxidized SNPs and B) SNPs ; C) Fluorescence peak 
intensity change at 550 nm as a function of SNP concentration; D) Fluorescence quenching 
efficiency of Dox as a function of SNP concentration. 
 
These titration experiments indicated oxidized SNPs with carboxyls can strongly adsorb 
cationic Dox by electrostatic interactions, while the non-oxidized SNPs can only physically trap 
Dox in the gel-like structure of the SNPs. This conclusion is further supported by experiments 
conducted with granular starch. These micrometer sized starch particles were involved because 
they can be easily precipitated out by centrifugation. We used granular starch and its oxidized 
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product to adsorb Dox. After the precipitation of granular starch and oxidized granules, we 
compared the fluorescence intensity of Dox in the supernatant with or without granular starch. 
We observed that no adsorption of Dox occurred with the normal starch granules but adsorption 
occurred with oxidized granules. Therefore, we proposed that Dox might be only physically 
trapped by the unmodified SNPs due to their gel-like structures; while oxidized SNPs can 
strongly bind Dox by electrostatic interactions. After adsorption, Dox molecules might aggregate 
to cause self-quenching.  
3.4.3 Release kinetics of Dox 
To measure the drug release profiles, Dox was loaded onto the unmodified SNPs and the 
oxidized SNPs. Released drugs were separated from SNPs using dialysis tube with a molecular 
weight cut off of 5,000. The release profiles of Dox are shown in Figure 24. The release of free 
Dox is compared with that of Dox loaded with oxidized SNPs and unmodified SNPs. The initial 
intensity is close to zero, indicating that little free drugs are present and the loading capacity is 
very high. Both free Dox and Dox in unmodified SNPs have a burst release in the first 7 hours. 
After 1 day, 90% of the initial amount of free Dox loaded into the dialysis tube was released; 
meanwhile, 50% of the initial amount of Dox with unmodified SNPs loaded into the dialysis tube 
was released. This result implied that a fraction of Dox was physically trapped by the unmodified 
SNPs. Compared to free Dox and Dox with unmodified SNPs, Dox loaded with oxidized SNPs 
showed a slower and sustained release profile. These results also indicated that Dox was 
successfully loaded into the oxidized SNPs. If the drugs were not loaded, a rapid release profile 
of free drugs would be observed. Free drugs can diffuse rapidly through the dialysis membrane. 
48 
 
 
Figure 24. The release profiles of free Dox and Dox adsorbed by unmodified SNPs and oxidized 
SNPs. 
 
Since weakly acidic environments are found endosomal and lysosomal compartments of 
tumor cells,128 Dox release profiles were monitored in both biologically neutral and acidic 
condition. Compared to a biologically neutral environment at pH 7.4, a faster release profile was 
observed in a tumor tissue environment at pH 5 as shown in Figure 25. These phenomena are 
consistent with previous studies about Dox release at different pHs.129–131 The reason for the 
faster release of Dox at pH 5 is that carboxylate anions on oxidized SNPs can be partially 
protonated under acidic conditions. Consequently, the electrostatic interactions between Dox and 
oxidized SNP are weakened, leading to more Dox being released.  
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Figure 25. Effect of  pH on Dox release profiles in oxdized SNPs. 
3.4.4 Toxicity of the conjugate 
After loading Dox onto oxidized SNPs, the toxicity of the drug conjugate was tested via 
incubation with HeLa cells. The MTT assay was performed to compare the toxicity of the 
vehicles, the free drug and the drug conjugate. Figure 26A shows that the oxidized SNPs are 
almost non-toxic as drug delivery vehicles, while drug conjugates kill cancer cells effectively in 
a certain concentration range. In Figure 26B, the efficacy of the drug conjugate is similar to that 
of the free Dox.  
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Figure 26. Comparison of toxicity of Dox/SNPs complexes with that of A) free oxidized SNPs 
and B) free Dox.  
3.5 Summary and future work 
This chapter reported the synthesis and characterization of carboxyl-modified SNPs and 
its capacity for drug loading. Doxorubicin was used as a model drug for the delivery study. Due 
to the positive charge of Dox, SNPs were functionalized with negatively charged carboxylate 
groups by TEMPO oxidation. The oxidation levels of SNPs were characterized by UV-vis 
absorption. The adsorption of Dox onto the oxidized SNPs was monitored by the fluorescence 
quenching of Dox. The adsorption titration experiments indicated that oxidized SNPs with 
carboxylate groups can strongly adsorb cationic Dox by electrostatic interactions, while the non-
oxidized SNPs can only physically trap Dox in their the gel-like structures. After Dox was 
loaded onto the SNPs, the efficacy of the drug conjugate was tested and compared to that of free 
Dox. A cell viability study demonstrated the comparable toxicity of the Dox/SNP complexes and 
free Dox. Meanwhile, sustained and slow release profiles of Dox were achieved in both 
biologically neutral and acidic environments.  
100 1000 10000
0
20
40
60
80
100
120
C
el
l V
ia
bi
lit
y 
(%
)
[Starch] (g/mL)
 SNPCOOH
 Dox/SNPCOOH
0.01 0.1 1
0
20
40
60
80
100
120
C
el
l V
ia
bi
lit
y 
(%
)
[Dox](M)
 Dox
 Dox/SNPCOOH
A B
51 
 
Since the level of crosslinking is partly responsible for the porosity of SNPs, which can 
be used to control the release rate, the effect of crosslinking densities on Dox release profiles 
should be studied in the future. Salt concentration also plays an important role in drug diffusion; 
therefore, the effect of salt in drug release profiles also needs to be tested. Due to the lack of time, 
the drug release profiles were not carried out in triplicate. The effect of oxidation levels of the 
SNPs on drug loading also can be investigated. Additionally, the quenched fluorescence 
intensities of Dox varied with time and pH, which made it hard to quantify the adsorption 
capacity of the oxidized SNPs for Dox. If reagents can be found to recover the quenched 
fluorescence of Dox, the drug loading capacity could be quantified in future work. To further 
understand the mechanism of fluorescence quenching between Dox and SNPs, fluorescence 
lifetime measurement can be performed in the future.  
3.6 Materials and methods  
3.6.1 Materials  
SNPs were supplied by EcoSynthetix Inc. (Burlington, ON, Canada). Dox, MTT, 
TEMPO, NaBr and 5% bleach were purchased from Sigma-Aldrich (St Louis, MO, US). HEPES, 
citrate acid and their sodium salt were from Mandel Scientific (Guelph, ON, Canada). Dialysis 
tube (cut-off = 5 kDa) was purchased from Spectrum Laboratories (Rancho Dominguez, CA). 
Aqueous solutions were prepared using Milli-Q water (18.2 MΩ resistivity).  
3.6.2 TEMPO oxidation and characterization  
5% (w/w) SNPs solution was prepared by dispersing 5 g of SNPs into 100 mL Milli-Q 
water at 80 °C. These were subject to TEMPO oxidation using methods discussed in the 
literature.36 5% w/w SNPs were slowly stirred with 47.5 mg TEMPO and 635 mg NaBr in Milli-
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Q water. Then 13 mL of 5% NaClO (bleach) was added to oxidized SNPs gradually. The pH of 
the solution should be maintained around 10.75 by adding 0.5 M NaOH for the reaction to 
proceed. The gradual addition process of bleach and NaOH was described in section 2.5.2. The 
reaction was quenched by adding 300 mL ethanol. Oxidized SNPs were precipitated out in 
ethanol. The precipitate was washed, centrifuged, and then lyophilized to form a white powder. 
Different oxidation levels of SNPs (1, 2, 5, 10, and 20%) were synthesized via adjusting the 
NaOH and bleach added. UV-vis spectroscopy was carried out for SNPs with different oxidation 
levels using an Agilent 8453 spectrophotometer. The SNPs samples with different oxidation 
levels used in UV-vis spectroscopy were papered in HEPES (pH 7.5) at a concentration of 0.1 
mg/mL. 
3.6.3 Drug loading and release 
The SNPs were fully dispersed to 5% (w/w) in PBS (pH 7.4) and citrate acid (pH 5), 
respectively. Next, doxorubicinHCl (Dox) was added to constitute 5% of the mass of SNPs. The 
Dox loaded SNPs (unmodified SNPs and oxidized SNPs) containing 5% Dox were dispersed in 
water at a concentration of 3 mg/mL and loaded in a dialysis tube Float-A-Lyzer® G2 from 
Spectrum Laboratories with MW cutoff at 5 kDa. This sample was then placed in a vial 
containing 35 mL of PBS or citrate acid with constant magnetic stirring and then allowed to sit 
for 120 hours at 36 °C. 400 µL samples were drawn off at 0, 0.5, 1, 2, 3, 4, 6, 10, 20, 24, 36, 48, 
52, 78 and 120 hours. The fluorescence spectra of 400 µL samples were collected using a Varian 
Cary Eclipse fluorescence spectrometer at room temperature. The excitation wavelength was set 
at 485 nm and then the emission peaks were scanned from 500 to 700 nm. 
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3.6.4 Cytotoxicity study of drug conjugate 
Cell culture and MTT assay. The toxicity study of the drug conjugate was performed 
using the same procedure described in Section 2.5.3. The only difference was the freshly 
prepared culture medium containing free Dox, free oxidized SNPs and SNP/Dox conjugates at 
the desired concentration. 
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Chapter 4 Cationic SNPs for gene delivery 
4.1 Introduction 
In this chapter, cationic SNPs were employed as vehicles for DNA delivery. Current gene 
delivery vehicles are mostly based on cationic polymers and cationic liposomes. While examples 
of inorganic nanoparticle-based delivery methods are also reported, their difficulty to degrade 
may pose safety concern. As SNPs are biodegradable and should have excellent biocompatibility, 
they are expected to be good candidates for gene delivery vehicles. However, the unmodified 
SNPs do not interact with DNA strongly. A logic method to increase DNA affinity is via cationic 
modification of SNPs. The size and surface charge of the cationic SNPs developed by my co-
worker Duncan Li were evaluated in this chapter. Meanwhile, the safe concentration range of the 
cationic SNPs used for gene delivery was determined by cell viability study. In order to balance 
the safety and efficiency of the gene delivery system, the ratios of cationic SNPs and DNA 
employed were carefully evaluated by gel retardation assay. Finally, the DNA complexes was 
delivered to HeLa cells with efficiency comparable to that of a commercial transfection reagent, 
Lipofectamine.  
4.2 Synthesis of cationic SNPs and characterization 
To synthesize cationic SNPs, my co-worker Duncan Li took the unmodified SNPs and 
introduced a cationic quaternary ammonium group onto the backbone of SNPs. Although starch 
has been modified with several types of cationic groups such as phosphonium and sulfonium 
groups, by far the most common approaches for cationic starch modifications are via introducing 
ammonium groups such as 3-chloro-2-hydroxypropyltrialkylammonium chlorides (CHPTMA).93 
As described in the reaction scheme presented in Figure 27, cationic SNPs were synthesized by 
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grafting CHPTMA onto SNPs under basic conditions. The degree of substitution for the cationic 
SNPs was determined by 1H-NMR. 
 
Figure 27. Synthesis process of cationic SNPs by introducing the cationic CHPTMA. 
 
To characterize the size of the cationically modified SNPs, DLS was employed to 
measure the hydrodynamic diameters of the cationic SNPs. Three types of cationic SNPs with 
different degrees of substitution (0.17, 0.24, 0.35) were dissolved in Milli-Q water and DMSO, 
respectively. The size distributions of the SNPs are similar in water and DMSO as shown in 
Figures 28A and 28B. According to the number based size distribution, 99.9% of the cationic 
SNPs were found to be between 9 to 30 nm depending on the degree of substitution. The size of 
the cationic SNPs is smaller than the unmodified SNPs, suggesting that degradation of the SNPs 
takes place during the cationic modification.  
 
 
 
SNPs Cationic SNPs CHPTMA  
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Figure 28 The number based size distribution of cationic SNPs in A) water and B) DMSO. 
 
To characterize the surface charge, the ζ-potentials of the cationic SNPs were measured. 
Compared with the unmodified SNPs, all of the cationic SNPs have positive surface charges as 
shown in Figure 29. With the degree of substitution increasing from 0.17 to 0.35, the ζ-potential 
of the cationic SNPs increased from 20 to 30 mV. These ζ-potential results demonstrated that the 
SNPs were successfully modified with positive surface charges. Meanwhile, the surface charge 
of the cationic SNPs increased with increasing degree of substitution. 
 
Figure 29 ζ-potentials of cationic SNPs with different degrees of substitution. 
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4.3 Toxicity of cationic starch nanoparticles  
Since we used cationic SNPs as vehicles for gene delivery, it is necessary to evaluate 
their cytotoxicity. Cationic SNPs, unmodified SNPs, and other commercial cationic reagents 
were incubated with HeLa cells to compare the cytotoxicity of these reagents. The MTT assay 
was conducted to measure cell viability and the results are summarized in Figure 30. Unmodified 
SNPs do not induce cell death when the concentration is lower than 10 mg/mL. However, 0.1 
mg/mL of cationic SNPs can cause 40% cell death. Similar toxicity can be observed for cationic 
SNPs with different degrees of substitution. In conclusion, no obvious trend can be observed 
between the toxicity and the degrees of substitution. All cationic SNPs are more toxic than 
unmodified SNPs as shown in Figure 30A. The reason is that most of the cell membranes have 
negative surface charges and cationic nanoparticles can penetrate into the cell membranes more 
easily causing damage to the cell membrane. As a result, particles with cationic charges are 
considered to be more toxic than neutrally or negatively charged particles. 
In order to compare the toxicity of cationic SNPs with other commercial transfection 
agents, cationic liposomes (lipofectamine, DOTAP) and cationic polymers (PEI) were also 
selected for incubation with HeLa cells. The concentrations of SNPs and other gene transfection 
agents were adjusted to achieve the same N/P ratio when used for complexation with DNA. N/P 
ratio is the molar ratio between positive nitrogen groups of cationic reagents and negative 
phosphate groups on the DNA backbone. As shown in Figure 30B, cells treated with the cationic 
SNPs can achieve 82% viability; while Lipofectamine, DOTAP, PEI result in 79%, 69% and 58% 
cell viability, respectively. These results indicated that the toxicity of cationic SNPs was slightly 
lower than other cationic agents at the same N/P ratio.  
58 
 
 
Figure 30. A) Toxicity of cationic SNPs with different degrees of substitution and B) Toxicity of 
cationic SNPs and other commercial cationic reagents at the same N/P ratio. 
4.4 DNA loading and release 
4.4.1 DNA binding property 
To further understand the binding property between DNA and cationic SNPs, we 
performed agarose gel electrophoresis experiments. Cationic SNP/DNA complexes formation is 
based on electrostatic interactions between the positive charges of cationic SNPs and the 
negative charges of DNA. The concentration of DNA was fixed; cationic SNPs were added to 
DNA to form cationic SNP/DNA complexes at various N/P molar ratios.  
In the gel image shown in Figure 31A, lane one is the free FAM-labeled DNA, which 
migrates towards the positive electrode as a strong band. With the concentration of cationic 
SNPs increasing, the bands are more retarded and show more smearing. All of the DNA is 
trapped in the well when the N/P ratio is reached 2.0, indicating DNA is adsorbed onto the 
cationic SNPs. It is worthy of note that if DNA is not adsorbed onto the cationic SNPs, the free 
DNA is supposed to migrate the same distance and run to the same position as shown in the case 
of DOTAP in Figure 31B. However, in the case of the cationic SNPs, the small size cationic 
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SNPs can migrate with DNA in the gel. With the concentration of the cationic SNPs increasing, 
the SNPs can associate with more DNA and trap the DNA in the well once the negative charges 
of DNA are neutralized by the cationic SNPs via electrostatic attractions. As shown in Figure 32, 
many DNA are adsorbed on the surface of the same SNPs at low N/P ratio. As a result, the 
negative charges of DNA are not completely neutralized by association with the cationic SNPs at 
low N/P ratio, resulting in the SNP/DNA complexes having a net negative charge. Due to the 
negative charge of SNP/DNA complexes, the cationic SNPs with a small size can migrate with 
DNA under the electric field. With the N/P ratio increasing, more positive charges of the cationic 
SNPs are available to interact with DNA. Meanwhile, the number of DNA adsorbed on the 
surface of each cationic SNPs is decreased as shown in Figure 32. As a result, the negative 
charge of cationic SNP/DNA complexes is neutralized. The mobility of the cationic SNP/DNA 
complexes is reduced. Finally, all of DNA is adsorbed by the cationic SNPs and the charge of 
cationic SNP/DNA complexes becomes neutral or positive, resulting in all the DNA complexes 
being trapped in the well.  
To confirm the above hypothesis, the interaction between cationic liposomes DOTAP 
with DNA was monitored as control groups. DOTAP is a cationic lipid that forms liposome with 
stable size range from 120 to 140 nm, which is not able to migrate in the gel. As shown in Figure 
31B, free DNA migrates to the same position as expected. With the N/P ratio increasing from 
0.125 to 4, more positive charges of the cationic liposomes are available to interact with DNA. 
Therefore, the amount of free DNA is decreased, resulting in less bright bands of free DNA. 
Meanwhile, the amount of DNA trapped by DOTAP liposomes increases inside the wells. In 
conclusion, gel electrophoresis experiments have confirmed the small size of SNPs; yet the 
cationic SNP/DNA complexes was stable enough to survive gel electrophoresis. Meanwhile, we 
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determined that two was the minimal N/P ratio for full complexation with DNA by gel 
retardation experiments.  
 
Figure 31 Gel image of the DNA interaction with A) cationic SNP, B) DOTAP. 
 
Figure 32. Interaction between DNA and cationic SNPs at different N/P ratios. 
4.4.2 Deliver DNA to cancer cells 
To compare the cell internalization efficiency of cationic SNPs with that of a commercial 
gene transfection agent, Lipofectamine, we examined the cellular uptake by laser scanning 
Low N/P ratio Free DNA High N/P ratio 
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confocal fluorescence microscopy after incubating DNA complexes with cancer cells. The 
confocal images of the cationic SNP/DNA, lipofectamine/DNA, and free DNA are shown in 
Figure 33. DNA was labeled with FAM shown in green. The nucleus areas were stained with 
blue. Cell borders were stained with yellow. The free DNA as the negative control group cannot 
cross the cell membrane. The cationic SNP/DNA complexes can go through the membrane and 
reaching the nucleus, achieving an internalization effect comparable to that observed with the 
commercial gene transfection agent, Lipofectamine.  
 
Figure 33. Cellular uptake images of cationic SNP/DNA complexes, lipofectamine/DNA 
complexes, and free DNA. 
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4.5 Summary and future Work 
This chapter reported the preparation and characterization of the cationic SNPs and their 
interactions with DNA. The cationic SNP/DNA complexes were delivered to cells with an 
efficiency comparable to that of a commercial gene transfer agent, Lipofectamine. The cationic 
SNPs were synthesized by my co-worker Duncan Li through the introduction of cationic 
quaternary ammonium groups onto the SNP backbone. After cationic modification, the cationic 
SNPs had a hydrodynamic diameter (Dh) around 10 nm with positive surface charge. Meanwhile, 
the cationic SNPs with a higher degree of substitution had a higher positive surface charge. In 
cytotoxicity study, the cationic SNPs showed lower toxicity than other commercially available 
gene transfection agents. After DNA was bound to the cationic SNPs by electrostatic 
interactions, the binding property was investigated by gel electrophoresis at different N/P molar 
ratios. We determined a the N/P ratio of 2.0 was the minimal ratio resulting in full complexation 
of the cationic SNPs with DNA. Furthermore, the successful DNA transfection was observed and 
the transfection efficiency was comparable to that of Lipofectamine, a commercial gene 
transfection agent. These results demonstrated the biocompatible potential of the cationic SNPs 
as a gene delivery platform. 
After binding DNA onto the cationic SNPs, the size and surface charge of the DNA/SNPs 
complexes should be measured. Since the mobility of sample loaded in gel depends on the size 
and charge of the sample, these measurements can help understand the results of gel retardation 
experiments. The gel retardation experiments also can be conducted using polyacrylamide gel 
due to its better resolution. The amount of DNA internalized by cell can be quantified using flow 
cytometry in the future.  
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4.6 Materials and methods  
4.6.1 Materials  
All SNPs were provided by EcoSynthetix Inc. (Burlington, ON, Canada). The cationic 
SNPs were synthesized by Duncan Li in Dr. Scott Taylor’s group at the University of Waterloo. 
DNA samples were purchased from Integrated DNA Technologies (IDT, Coralville, IA). The 
FAM-labeled 24-mer DNA sequence is FAM-ACGCATCTGTGAAGAGAACCTGGG. DOTAP 
was purchased from Avanti Polar Lipids (Alabaster, AL). Lipofectamine 2000 was purchased 
from Invitrogen. HEPES and DMSO were purchased from Mandel Scientific Inc. (Guelph, ON, 
Canada). HeLa cell line (CCL-2TM) was obtained from the American Type Culture Collection 
(ATCC, Manassas, Virginia) through the help of the laboratory of Dr. Shirley Tang (Waterloo, 
Ontario). MTT was purchased from Sigma-Aldrich (St Louis, MO). Agarose powder (50004) 
was purchased from Ornat. All the buffers and solutions were prepared with Milli-Q water. 
4.6.2 Dynamic light scattering (DLS) and ζ-potential measurements  
To obtain pH-dependent size and ζ-potential, cationic SNPs with different degrees of 
substitution (1 mg/mL) were dispersed in designed 5 mM HEPES buffer solutions (pH 7.5). The 
hydrodynamic sizes of SNPs were measured using a dynamic light scattering (Zetasizer Nano 90, 
Malvern). The reported size was the average diameter (number based) of three runs. Each run 
consisted of ten measurements for 1 min each. The same samples were used for ζ-potential 
measurement on a Malvern Zetasizer Nano ZS90 at  90°  collecting  optics. Averages of three 
runs were made. The data were analyzed by Malvern Dispersion Technology Software 4.20.   
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4.6.3 Cytotoxicity study of cationic SNPs 
Cell culture and MTT assay. The toxicity study of the conjugate was performed using 
the same procedure described in Section 2.5.3. The only difference was the freshly prepared 
culture medium containing cationic SNPs with different degrees of substitution (0.17, 0.24, 0.36) 
at the desired concentration. The concentration of SNPs and other gene transfection agents were 
adjusted by achieving a same N/P ratio with DNA. The concentrations of cationic SNP, 
lipofectamine, DOTAP, and PEI were 20 μg/mL, 1μL/20 μL, 100μg/mL and 25 μg/mL, 
respectively.  
4.6.4 Preparation of cationic SNP/DNA and liposome/DNA complexes 
Agarose gel electrophoresis.  The binding between cationic SNPs and FAM-DNA was 
investigated by agarose gel electrophoresis. The complexes of cationic SNP, DOTAP and FAM-
DNA were prepared at various N/P molar ratios (0.25, 0.5, 1, 1.5, 2, 4). The concentration of 
FAM-DNA was fixed at 100 nM. The concentrations of cationic SNPs and liposomes were tuned 
according to the required N/P ratio. Free FAM-DNA (100 nM) was also included for comparison. 
The gel was prepared with 2% agarose and 1× TBE (pH 7). 40 μL of DNA-cationic 
SNP/liposome conjugates containing 50% glycerol were added to each lane. The gel was run at 
120 V for 40 mins. The running buffer is 1× TBE (pH 7). The FAM-DNA bands were imaged 
using a gel documentation system (Chemidoc-MP, Bio-Rad). 
Preparation of liposomes. 1) Preparation of lipids film: 2.5 mg of DOTAP lipids were 
dissolved in chloroform. Then chloroform was evaporated to form a lipid film using gentle a N2 
flow. The lipid film was further dried to remove the residual chloroform by placing the samples 
in a vacuum oven overnight. The dried lipid film was kept under N2 and the container was taped 
tightly and stored at -20 °C until ready to hydrate. 2) Hydration of lipid film: The hydration of 
65 
 
the dry DOTAP film was performed by adding 0.5 mL buffer A (100 mM NaCl, 10 mM HEPES, 
pH 7.6) to the container at room temperature. Finally, the concentration of lipid was 5 mg/mL. 
Then the suspension was occasional sonicated for 2 h to form a cloudy suspension. 3) Sizing of 
lipid suspension: the DOTAP liposomes were prepared using the standard extrusion process. A 
mini-extruder from Avanti was used to maintain the mean diameter of DOTAP liposome around 
120-140 nm. The resulting cloudy suspension was forced through two stacked polycarbonate 
filter membrane (pore size =100 nm) for 21 times to downsize the lipid dispersion. After 
extrusion, the transparent lipid solution suggested the formation of liposomes. 
4.6.5 Cellular uptake of cationic SNP/DNA complexes 
Laser scanning confocal fluorescence microscopy. Cellular uptake of cationic 
SNP/DNA complexes was visualized using a confocal microscope. HeLa cells were seeded onto 
14 mm coverslips in 24-well plates at a density of 50,000 cells per well. 500 μL of cell medium 
was added to culture cells and allowed to grow to ~60% confluency. In the cellular uptake 
experiment, the cells were incubated with cationic SNP/DNA, lipofectamine/DNA, and free 
DNA at N/P ratio two for 3 h at 37 °C. The concentration of DNA was fixed at 200 nM. The 
concentrations of cationic SNPs and liposome were tuned according to the N/P ratio. After the 
designated incubation time 2h, the cells were washed twice with PBS buffer and fixed by 4% 
paraformaldehyde (in PBS buffer) for 15 min at room temperature. The cells were further 
washed three times with PBS. Then the cell actin was stained with Alexa Fluor 488 phalloidin 
and the cell nuclei were stained with DAPI by the incubation for 5 min according to the 
manufacturer’s procedures. Images of cells were captured using DAPI and Alexa Fluor 488 
channels under a laser scanning confocal fluorescence microscope (LSM510Meta, CarlZeiss Inc., 
Thornwood, NY). 
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Chapter 5 Conclusions and recommendations  
5.1 Conclusions 
This thesis began with an overview of the advantages of nanocarriers and an introduction 
of nanomaterials applied as drug and gene delivery vehicles. After a literature review about the 
applications of different nanomaterials in drug delivery systems, SNPs were proposed to be good 
candidates for drug delivery due to their good biocompatibility. The chemical structure and 
properties of starch and SNPs were discussed. Different preparation methods and chemical 
modifications of SNPs were then presented. After reviewing the relevant work related to the use 
of SNPs as nanocarriers, we explored the applicability of the modified SNPs for drug and gene 
delivery. With this in mind, this thesis was divided into the three following sections: 1) The 
study of the toxicity of SNPs supplied by EcoSynthetix and the development of a method to 
eliminate their toxicity; 2) the synthesis and characterization of carboxylated SNPs for Dox 
delivery; and 3) the characterization of cationically modified SNPs for delivering DNA into 
cancer cells. These objectives sought to establish SNPs as a new platform for drug and gene 
delivery. An overview of the conclusions reached in this thesis is provided hereafter. 
Glyoxal used as a crosslinking agent in the preparation of SNPs was found to be at the 
origin of the toxicity of the SNPs. The toxicity of the SNPs is believed to result from the reaction 
of glyoxal with the amino groups of proteins, nucleotides, and lipids. The products of these 
reactions appear to cause cell damage. The toxicity of the unmodified SNPs increased with 
increasing crosslinker density. In an interesting experiment, the GX0 sample spiked with an 
amount of glyxoal similar to that used by Ecosynthetix to prepare the GX5 sample had a similar 
toxicity as that of the GX5 SNP. These results demonstrated that unbound glyoxal is the source 
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of the toxicity of the SNPs. Fortunately, these free glyoxal molecules can be removed by 
washing the SNPs with ethanol resulting in glyoxal-free SNPs that were almost non-toxic.  
SNPs were also carboxylated by TEMPO oxidation. The oxidation of starch mediated by 
TEMPO can selectively oxidize the primary hydroxyls of the SNPs into carboxyl acids. The 
oxidation level of the SNPs was characterized by UV-vis absorption. The size and surface charge 
of the SNPs with different oxidation levels were also determined. The positively charged 
Doxorubicin (Dox) was used as a model drug and it could bind strongly onto the oxidized SNPs 
by electrostatic interactions. The orange fluorescence of Dox was quenched by the addition of 
the oxidized SNPs. As a result, fluorescence quenching of Dox was employed to characterize its 
binding onto the carboxylated SNPs. Titration of Dox with the oxidized SNPs and the 
unmodified SNPs demonstrated strong binding of Dox onto the oxidized SNPs by electrostatic 
interactions. Residual binding of Dox onto the unmodified SNPs was attributed to physical 
trapping of Dox in the gel-like structure of the SNPs. By comparing the drug release profiles of 
Dox loaded onto the oxidized SNPs with that of free Dox and Dox bound to the unmodified 
SNPs, a sustained and slow release profile of Dox loaded onto the oxidized SNPs was observed 
in both biologically neutral and acidic conditions. After incubating the Dox/SNPs complexes 
with HeLa cells, the drug complexes could kill the cells effectively.  
Cationic SNPs were also investigated in this thesis. The cationic SNPs were modified 
with cationic quaternary ammonium groups. The size and surface charge of the cationic SNPs 
were characterized. The cationic SNPs had a hydrodynamic diameter (Dh) around 10 nm in 
DMSO and water. Comparison of the Dh values obtained with the modified and unmodified 
SNPs led to the conclusion that the cationic SNPs were smaller, indicating some level of 
degradation during the cationic modification. Three cationic SNPs with different degrees of 
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substitution were investigated. All modified SNPs showed a positive surface charge with the 
SNPs having a higher degree of substitution yielding higher surface charges. These results based 
on ζ-potential measurements demonstrated successful cationic modification of the SNPs. The 
toxicity of the modified SNPs was evaluated by using different SNP concentrations in the MTT 
assay. The result provided a safe concentration range where the cationic SNPs could be applied 
to gene delivery. In comparison with other commercially available cationic agents, the toxicity of 
the cationic SNPs was found to be slightly lower. The DNA binding process was investigated by 
gel retardation experiments. These experiments led to the conclusion that a N/P ratio of 2.0 was 
the minimal ratio to yield full complexation of the cationic SNPs with DNA. After binding DNA 
onto the cationic SNPs by electrostatic interactions, cellular uptake of the DNA/SNPs complexes 
was achieved and the uptake efficiency was comparable to that of Lipofectamine, a commercial 
gene transfection agent. 
 
5.2 Recommendations for future work 
The results described in this thesis lead to a number of recommendations for the 
development of SNPs as nanocarriers for drug and gene delivery. These recommendations are 
summarized as follows: 1) Enhancement of the biocompatibility of the unmodified SNPs; 2) 
enhancement of the efficacy of the delivery systems; 3) immune response test for the drug 
complexes; 4) evaluation of the therapeutic effect of the complexes in vivo. 
 
1) Enhancement of the biocompatibility of the unmodified SNPs  
Since the free glyoxal molecules are responsible for the toxicity of the SNPs, the origin of 
the free glyoxal should be studied in the future. There are two possible sources: 1) some glyoxal 
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molecules are not involved in the crosslinking process during the manufacturing of the SNPs; 2) 
some glyoxal molecules are released from the SNPs when dispersed in water due to the 
reversible crosslinking reaction. The inherent toxicity of glyoxal mandates that other 
biocompatible and stable crosslinking agents such as sodium trimetaphosphate (STMP) be 
investigated to crosslink the SNPs instead of glyoxal.  
2) Enhancement of the efficacy of the delivery systems  
Some clinical studies have shown that the incorporation of more than one anti-cancer 
drug can enhance anticancer efficiency by a synergistic effect.36 Most reported polysaccharide 
platforms are based on Dox delivery, but the work on cisplatin is limited. Cisplatin, as another 
common anticancer drug, also has a number of problems such as low solubility and 
cardiotoxicity. Since Dox and cisplatin have drastically different chemical structures, properties, 
and efficacy, multiple drugs could be loaded to the SNPs and delivered to improve their anti-
cancer efficacy. However, different drugs might compete for the surface binding sites on the 
SNPs when co-delivered. Subsequent studies about co-delivery of cisplatin and Dox can be 
explored in the future. It is expected that co-delivery of cisplatin and Dox would suppress cancer 
growth more efficiently than individual drugs. 
Since small interfering RNA (siRNA) and micro RNA (miRNA) can induce gene 
silencing by targeting specific genes, their delivery and inhibition effect on gene expression can 
be performed by cationic SNPs. Subsequent studies on the function of nucleic acids in terms of 
the suppression of gene expression can be further explored. The co-delivery of gene and small 
molecular drugs such as Dox and cisplatin are also worth exploring in future work. Currently, 
common gene delivery vehicles are expensive and may pose safety concern, depending on their 
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chemical structures. The cationic SNPs might be a cost-effective method to improve gene 
transfection efficacy. 
3) Immune response test for the drug complexes 
Drug complexes are foreign to the body, and as such, can be recognized by the immune 
system and activate the immune response when circulating in the bloodstream. Phagocytic cells 
participating in inflammation represent a major part of the body’s immune mechanism.132 
Therefore, the immune response of macrophages treated with drug complexes should be 
evaluated in future work. 
4) Evaluation of the therapeutic effect of the complexes in vivo 
After promising drug/SNP complexes are recognized, it should be examined with in vivo 
experiments using animal models bearing tumors. However, the cost of an in vivo study is much 
higher than that of an in vitro study. Therefore, the drug/SNP complexes should be optimized to 
have the best stability and biocompatibility. Different cancer cell lines should also be tested for 
this drug delivery system. 
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